Christopher Su
YOU?
Author Swipe
View article: Association of social vulnerability index and chimeric antigen receptor T-cell therapy administration, 2018-2023
Association of social vulnerability index and chimeric antigen receptor T-cell therapy administration, 2018-2023 Open
Chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory hematologic malignancies demands numerous visits, which may pose challenges for patients with lower socioeconomic status (SES). The Centers for Disease …
View article: Using credit data to detect financial hardship in patients with multiple myeloma and associations to treatment outcomes
Using credit data to detect financial hardship in patients with multiple myeloma and associations to treatment outcomes Open
View article: Medical Debt—An Iatrogenic Epidemic With Mortal Consequences
Medical Debt—An Iatrogenic Epidemic With Mortal Consequences Open
If medical debt were a chronic illness, it would be more common than coronary artery disease, diabetes, or cancer.But is it deadly?This is the central question posed by Han et al, 1 who used countylevel records to explore the associations …
View article: Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways
Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways Open
Immunotherapy has transformed lung cancer management, but PSC remains an aggressive subtype with a poor prognosis. This study investigates the differential expression of PD-L1 and alternative immune checkpoints (ICs; B7x, B7-H3, and HHLA2)…
View article: Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 Open
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe…
View article: Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 Open
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
View article: Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 Open
Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
View article: Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 Open
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe…
View article: Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data
Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data Open
Click to increase image sizeClick to decrease image size Disclosure statementNo potential conflict of interest was reported by the author(s).Author contributionsCTS, JBS: conception and design; CTS: data acquisition and analysis; CTS, JCC,…
View article: Defining the Role of the Modern Oncology Provider in Mitigating Financial Toxicity
Defining the Role of the Modern Oncology Provider in Mitigating Financial Toxicity Open
View article: Differential responses to taxanes and PARP inhibitors in <i>ATM‐</i> versus <i>BRCA2</i>‐mutated metastatic castrate‐resistant prostate cancer
Differential responses to taxanes and PARP inhibitors in <i>ATM‐</i> versus <i>BRCA2</i>‐mutated metastatic castrate‐resistant prostate cancer Open
Background PARP (poly(ADP‐ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair (DDR) pathways, but patients with ATM ‐ …
View article: Shifts in Multiple Myeloma Care Utilization of Veterans in the COVID-19 Era: Interrupted Time Series Analysis of Veterans Health Administration Data
Shifts in Multiple Myeloma Care Utilization of Veterans in the COVID-19 Era: Interrupted Time Series Analysis of Veterans Health Administration Data Open
Introduction The COVID-19 pandemic profoundly impacted medical care delivery and ushered in an era of telemedicine and virtual care. However, shifts in multiple myeloma (MM) care utilization patterns as a consequence of the COVID-19 pandem…
View article: Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma Open
Ocular immune-related adverse events are a relatively rare complication of immune checkpoint inhibitors. Common ocular toxicities range from dry eyes to inflammatory uveitis and ocular myasthenia gravis. Here, we present the case of a 55-y…
View article: Financial Toxicity Interventions in Hematologic Malignancies Are Timely and Necessary
Financial Toxicity Interventions in Hematologic Malignancies Are Timely and Necessary Open
View article: Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014–2020
Divergent Patterns in Care Utilization and Financial Distress between Patients with Blood Cancers and Solid Tumors: A National Health Interview Survey Study, 2014–2020 Open
Introduction: Important differences exist between the presentation, treatment, and survivorship of patients and survivors with blood cancers. Furthermore, existing research in financial toxicity has not fully addressed the relationship bet…
View article: Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium
Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium Open
View article: Table of contents
Table of contents Open
View article: Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study Open
Background Enfortumab vedotin (EV) is a novel antibody‐drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, the aut…
View article: Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 Open
The findings of this cohort study suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic cancers and COVID-19.
View article: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond Open
View article: Differential Activity of PARP Inhibitors in<i>BRCA1</i>- Versus<i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer
Differential Activity of PARP Inhibitors in<i>BRCA1</i>- Versus<i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer Open
PURPOSE Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but th…
View article: Affordable Care Act and Cancer Survivors' Financial Barriers to Care: Analysis of the National Health Interview Survey, 2009-2018
Affordable Care Act and Cancer Survivors' Financial Barriers to Care: Analysis of the National Health Interview Survey, 2009-2018 Open
PURPOSE: Since Affordable Care Act (ACA) implementation in 2014, studies have demonstrated gains in insurance coverage for cancer survivors < 65 years. We assessed the impact of ACA implementation on financial barriers to care by stratifyi…
View article: A Scoping Review of Behavioral Interventions Addressing Medical Financial Hardship
A Scoping Review of Behavioral Interventions Addressing Medical Financial Hardship Open
Little information has been compiled across studies about existing interventions to mitigate issues of medical financial hardship, despite growing interest in health care delivery. The purpose of this qualitative systematic scoping review …
View article: Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration Open
Objectives To evaluate outcomes of patients achieving a post‐treatment pathological stage of
View article: Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19 Open
Summary Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults wi…
View article: Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors Open
View article: Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma Open
The findings of this multicenter cohort study suggest that ICI rechallenge in patients with mRCC may be safe and reasonably efficacious, with an overall response rate of 23%. Data from prospective studies are needed to validate these findi…
View article: Derivation of a Model to Guide Empiric Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection in an Endemic Area
Derivation of a Model to Guide Empiric Therapy for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection in an Endemic Area Open
Background Appropriate therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection (BSI) is often given late in the course of infection, and strategies for identifying CRKP BSI earlier are needed. Methods A retrospe…
View article: Survival Disparities in Black Patients With EGFR-mutated Non–small-cell Lung Cancer
Survival Disparities in Black Patients With EGFR-mutated Non–small-cell Lung Cancer Open
View article: Reality First
Reality First Open
An 83-year-old woman is admitted to the medical floor with a diagnosis of pulmonary embolism seen on ventilation/perfusion scan. A common condition affecting more than 5 per 1000 individuals over the age of 75 years, pulmonary embolism is …